Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder
Status:
Terminated
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This will be a 12-week open-label pilot treatment study for children and adolescents (ages
6-17) who meet DSM-IV criteria for bipolar disorder (BPD) and obsessive-compulsive disorder
(OCD) who are adequately mood stabilized on a stable regimen based on standard clinical care.
Specific hypotheses are as follows:
Hypothesis 1: Children and adolescents with comorbid OCD and BPD who have achieved adequate
mood stabilization using a naturalistic clinical practice approach, will benefit from an
FDA-approved selective seratonin reuptake inhibitor (SSRI) on their OCD symptoms in a
clinically meaningful way without exacerbation of bipolar symptoms.